Share on LinkedInShare on LinkedIn

ARTICLE · 14 MARCH 2013

Federal Court delivers significant judgment allowing launch of generic CRESTOR (rosuvastatin)

This judgment allows the many generic pharmaceutical companies with ARTG registrations to launch rosuvastatin products.

AustraliaIntellectual Property

Introduction

Justice Jagot of the Federal Court of Australia has found three patents protecting AstraZeneca's CRESTOR (rosuvastatin) product invalid.

The revocation of the low dose HeFH and cation patents, subject to any appeal by AstraZeneca, opens the door for the many generic pharmaceutical companies with ARTG registrations (including those not party to the proceedings) to launch rosuvastatin products.

AstraZeneca has not yet announced an appeal against the judgment, but has issued a press release saying it is considering all legal options.

Of particular interest to originators and generics alike is the approach of the Court to the question of the "starting point" for the purposes of assessing inventive step. We consider this, and some other aspects of the decision, below.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from